BioAge Labs (NASDAQ:BIOA) Stock Price Down 6% – Should You Sell?

BioAge Labs, Inc. (NASDAQ:BIOA) shares dropped 6% during mid-day trading on Friday . The stock traded as low as $16.74 and last traded at $16.7160. Approximately 78,899 shares changed hands during trading, a decline of 89% from the average daily volume of 705,451 shares. The stock had previously closed at $17.79.

Analyst Upgrades and Downgrades

BIOA has been the topic of several research analyst reports. Needham & Company LLC started coverage on BioAge Labs in a research note on Friday, March 27th. They set a “buy” rating and a $50.00 target price on the stock. Morgan Stanley set a $23.00 price target on BioAge Labs in a research note on Wednesday, February 4th. Citigroup upped their price target on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Piper Sandler started coverage on BioAge Labs in a research note on Tuesday, January 27th. They issued an “overweight” rating on the stock. Finally, Oppenheimer started coverage on BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.25.

BioAge Labs Price Performance

The company has a market capitalization of $718.51 million, a PE ratio of -7.23 and a beta of 1.80. The company has a 50 day moving average of $19.45 and a two-hundred day moving average of $13.89.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.11. BioAge Labs had a negative return on equity of 27.86% and a negative net margin of 896.11%.The company had revenue of $3.08 million for the quarter.

Insider Transactions at BioAge Labs

In other news, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the sale, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. This represents a 54.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Paul D. Rubin sold 7,433 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 267,540 shares of company stock valued at $4,895,168. Insiders own 20.82% of the company’s stock.

Institutional Investors Weigh In On BioAge Labs

A number of institutional investors have recently modified their holdings of BIOA. Geode Capital Management LLC grew its stake in shares of BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after acquiring an additional 171,426 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of BioAge Labs in the second quarter worth $64,000. Marshall Wace LLP grew its stake in shares of BioAge Labs by 324.7% in the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after acquiring an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after acquiring an additional 5,976 shares during the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in shares of BioAge Labs in the second quarter worth $182,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.